Literature DB >> 8272196

The neuropeptide bradykinin stimulates phosphoinositide turnover in HSDM1C1 cells: B2-antagonist-sensitive responses and receptor binding studies.

N A Sharif1, R L Whiting.   

Abstract

Bradykinin (BK) and its analogs (1 nM-100 microM) stimulated phosphoinositide (PI) turnover in murine fibrosarcoma (HSDM1C1) cells in a concentration-dependent manner. The relative potencies (EC50) were: BK = 48 +/- 4 nM; Lys-BK = 39 +/- 3 nM; Met-Lys-BK = 158 +/- 33 nM, Des-Arg9-BK = 2617 +/- 598 nM (means +/- SEM, n = 3-14). All these analogs were full agonists and they produced up to 5.4 +/- 0.4-fold stimulation of PI turnover at the highest concentration (10-100 microM) of the peptides. In contrast, the analogs [D-Arg0-HYP3-Thienyl5,8-D-Phe7]-BK (HYP3-antagonist), [D-Arg0-HYP3-Thienyl,5,8-D-Phe7]-BK (Thienyl antagonist) and Des-Arg9-Leu8-BK were inactive, as agonists, at 0.1 nM-1 microM in this system. These data suggested that BK-induced PI turnover in these cells was mediated via B2-type of BK receptors. This was confirmed further by the fact that both the B2-selective Hyp3- and Thienyl-antagonists inhibited BK-induced PI turnover with KBS of 369 +/- 51 nM and 368 +/- 118 nM respectively while the B1-selective antagonist, Des-Arg9-Leu8-BK, was inactive at 1 microM. [3H]BK receptor binding studies revealed two binding sites, one with high affinity (Kd = 0.24 +/- 0.06 nM; Bmax = 1.4 +/- 0.4 pmol/g tissue) and the other with low affinity (Kd = 18.5 +/- 0.95 nM; Bmax = 25.1 +/- 0.52 pmol/g tissue), on HSDM1C1 cell homogenates. The rank order of affinity of BK analogs at inhibiting specific [3H]BK binding was similar to that found for PI turnover.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8272196     DOI: 10.1007/bf00975053

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  49 in total

Review 1.  New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization.

Authors:  D Regoli; N E Rhaleb; S Dion; G Drapeau
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

2.  New synthetic antagonists of bradykinin.

Authors:  M Schachter; Y Uchida; D J Longridge; T Labedz; E T Whalley; R J Vavrek; J M Stewart
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

3.  Bradykinin receptor-mediated cyclic GMP formation in a nerve cell population (murine neuroblastoma clone N1E-115).

Authors:  R M Snider; E Richelson
Journal:  J Neurochem       Date:  1984-12       Impact factor: 5.372

4.  A phosphoinositide-linked peptide response in astrocytes: evidence for regional heterogeneity.

Authors:  A J Cholewinski; M R Hanley; G P Wilkin
Journal:  Neurochem Res       Date:  1988-04       Impact factor: 3.996

5.  Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions.

Authors:  L R Steranka; D C Manning; C J DeHaas; J W Ferkany; S A Borosky; J R Connor; R J Vavrek; J M Stewart; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

6.  Two bradykinin binding sites with picomolar affinities.

Authors:  D C Manning; R Vavrek; J M Stewart; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1986-05       Impact factor: 4.030

7.  Regulation of prostaglandin synthesis mediated by thrombin and B2 bradykinin receptors in a fibrosarcoma cell line.

Authors:  P R Becherer; L F Mertz; N L Baenziger
Journal:  Cell       Date:  1982-08       Impact factor: 41.582

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Bradykinin-induced stimulation of afferent fibres is mediated through protein kinase C.

Authors:  A Dray; J Bettaney; P Forster; M N Perkins
Journal:  Neurosci Lett       Date:  1988-09-12       Impact factor: 3.046

10.  Differential receptor occupancy requirements for muscarinic cholinergic stimulation of inositol lipid hydrolysis in brain and in neuroblastomas.

Authors:  S K Fisher; R M Snider
Journal:  Mol Pharmacol       Date:  1987-07       Impact factor: 4.436

View more
  3 in total

1.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

2.  M3 muscarinic receptors on murine HSDM1C1 cells: further functional, regulatory, and receptor binding studies.

Authors:  N A Sharif; Z P To; K H Wong; R E Delmendo; R L Whiting; R M Eglen
Journal:  Neurochem Res       Date:  1995-01       Impact factor: 3.996

3.  Protein expression, biochemical pharmacology of signal transduction, and relation to intraocular pressure modulation by bradykinin B₂ receptors in ciliary muscle.

Authors:  Najam A Sharif; Shouxi Xu; Linya Li; Parvaneh Katoli; Curtis R Kelly; Yu Wang; Shutong Cao; Rajkumar Patil; Shahid Husain; Laura Klekar; Daniel Scott
Journal:  Mol Vis       Date:  2013-06-15       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.